Age group: From 18 years old
Gender: Male or Female
Duration: Up to 52 weeks approximately
Compensation: Up to $1,150
About this study:
Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naïve Subjects with Active Psoriatic Arthritis II.To
evaluate the efficacy of tildrakizumab compared to placebo in anti-Tumour Necrosis Factor (TNF) naïve subjects with active psoriatic arthritis (PsA) as measured by the proportion of subjects achieving a 20% reduction from Baseline in American College of Rheumatology response criteria [ACR20] .
Who can participate?
.Participants must be from 18 years old with diagnosis of active PsA for at least 6 months before the first administration of the study agent and has active PsA confirmed at Screening and Baseline.Subjects must have no prior exposure to anti-tumor necrosis factor (anti-TNF) agent(s) for the treatment of PsO or PsA.
Where is the study taking place?
The study is being conducted at our facility in Palmetto Medical Plaza.
NCT04314531
